Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
DocCheck AG (AJ91.DE)
Cologne, DE
DocCheck AG offers community, agency, and e-commerce services for the healthcare sector in Europe. The company develops and implements communication strategies for media on healthcare and business-to-business sectors; sells medical supplies and medical technology primarily via mail order to various medical professional groups, and invests in healthcare sectors, as well as involved in online advertising, market research, online studies, and paid content for healthcare market players. It also operates platform for information exchange, online services, and e-commerce in this market. DocCheck AG was founded in 1990 and is based in Cologne, Germany.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.41% | -3.70% | -4.41% | +0.78% | +14.04% | +3.17% | +10.17% | -2.26% | -54.06% | +65.61% | +343.69% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Distribution: +5.6%+2.8% Q4'25: +5.8% (vs Q4'23)
-
EPS growth Medical - Distribution: +4.9%+1.0% Q4'25: +418.2% (vs Q4'23)
-
FCF margin FCF growth · Medical - Distribution: +37.6%+3.4% Q4'25: -1.1% (vs Q4'23)
-
EBIT margin Medical - Distribution: +3.0%+13.8% ★ Q4'25: +15.1% (vs Q4'23)
-
ROIC Medical - Distribution: +5.7%+17.9% ★ Q4'25: +41.8% (vs Q4'23)
-
Share dilution Medical - Distribution: +0.0%+0.0% Q4'25: 0.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×0.40× ★ Q4'25: 0.18× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2000 actual |
Dec 2001 actual |
Dec 2002 actual |
Dec 2005 actual |
Dec 2006 actual |
Dec 2007 actual |
Dec 2008 actual |
Dec 2009 actual |
|---|---|---|---|---|---|---|---|---|
| Revenue |
9.86M
est.
|
15.63M
est.
|
13.29M
est.
|
11.20M
est: 10.97M (+2.1%)
|
13.60M
est: 12.99M (+4.6%)
|
14.69M
est: 14.72M (-0.2%)
|
15.44M
est: 16.80M (-8.1%)
|
16.32M
est: 19.46M (-16.1%)
|
| EBITDA |
2.11M
est.
|
4.11M
est.
|
3.45M
est.
|
1.37M
est: 2.30M (-40.6%)
|
2.58M
est: 2.73M (-5.5%)
|
874.4K
est: 3.09M (-71.7%)
|
1.11M
est: 2.31M (-51.7%)
|
2.00M
est: 4.19M (-52.2%)
|
| EBIT |
1.63M
est.
|
1.05M
est.
|
714.0K
est.
|
1.58M
est: 1.78M (-11.3%)
|
2.10M
est: 2.11M (-0.6%)
|
331.4K
est: 2.39M (-86.1%)
|
1.14M
est: 382.3K (+197.6%)
|
1.13M
est: 3.24M (-65.1%)
|
| Net Income |
373.8K
est.
|
1.20M
est.
|
1.10M
est.
|
668.9K
est: 515.0K (+29.9%)
|
943.7K
est: 757.8K (+24.5%)
|
664.0K
est: 978.5K (-32.1%)
|
601.3K
est: 764.6K (-21.3%)
|
610.0K
est: 1.85M (-67.1%)
|
| SGA |
366.7K
est.
|
5.28M
est.
|
5.33M
est.
|
—
est: 400.0K (-100.0%)
|
—
est: 473.6K (-100.0%)
|
—
est: 536.6K (-100.0%)
|
—
est: 6.42M (-100.0%)
|
—
est: 727.3K (-100.0%)
|
| EPS |
0.07
est.
|
0.22
est.
|
0.17
est.
|
0.11
est: 0.10 (+7.8%)
|
0.16
est: 0.15 (+4.6%)
|
0.12
est: 0.19 (-38.1%)
|
0.11
est: 0.26 (-58.1%)
|
0.11
est: 0.36 (-69.7%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-28 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-27 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-26 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-25 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-22 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-21 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-20 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-19 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-18 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-15 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-14 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-13 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-12 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-11 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-06 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-05 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-04 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-29 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Thilo Kolzer | Chief Operating Officer & Member of Management Board | 254.1K | male |
| Frank Nicolas Antwerpes | President of the Management Board & Chief Executive Officer | 250.8K | — |
| Philip Stadtmann | Chief Financial Officer & Member of Management Board | 233.0K | male |
| Jens Knoop | Chief Technology Officer & Member of Management Board | 195.7K | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AJ91.DE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
